Abstract
The prevalence of comorbidities in individuals with neurodevelopmental disorders (NDD) is not well understood, while these are important for accurate diagnosis and prognosis in routine care and for characterizing the clinical spectrum of NDD syndromes. Therefore, we developed PhenomAD-NDD: an aggregated database with comorbid phenotypic data of 51,227 individuals with NDD, all harmonized into Human Phenotype Ontology (HPO), with in total 3,054 unique HPO terms. We demonstrate that almost all congenital anomalies are more prevalent in the NDD population than in the general population and the NDD baseline prevalence allows for approximation of enrichment of symptoms. Such analyses for 33 genetic NDDs for instance shows that 32% of enriched phenotypes is currently not reported in the clinical synopsis in OMIM. PhenomAD-NDD is open to all via a visualization online tool and allows to determine enrichment of symptoms in NDD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We are grateful to the Dutch Organisation for Health Research and Development: ZON-MW grants 912-12-109 (to B.B.A.d.V. and LELMV), Donders Junior researcher grant 2019 (B.B.A.d.V. and LELMV), and Aspasia grant 015.014.066 (to LELMV). The aims of this study contribute to the Solve-RD project (to LELMV), which has received funding from the European Unions Horizon 2020 research and innovation program under grant agreement No 779257. Multiple authors of this publication are members of the European Reference Network on Rare Congenital Malformations and Rare Intellectual Disability ERN-ITHACA [EU Framework Partnership Agreement ID: 3HP-HPFPA ERN-01-2016/739516] The funder(s) of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The medical ethical review board of the Radboud university medical center approved the use of data for the purpose of this study (#2018-4733).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The contents of PhenomAD-NDD are freely available online at (https://humandiseasegenes.nl/phenomadndd/). There, a tool to calculate enrichment of symptoms for your own dataset is available as well.
Data Availability Statement
The contents of PhenomAD-NDD are freely available online at (https://humandiseasegenes.nl/phenomadndd/). There, a tool to calculate enrichment of symptoms for your own dataset is available as well.